Salarius Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SLRX and other ETFs, options, and stocks.

About SLRX

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor.

CEO

David J. Arthur

CEODavid J. Arthur

Employees

Employees2

Headquarters

Houston, Texas

HeadquartersHouston, Texas

Founded

2014

Founded2014

Employees

Employees2

SLRX Key Statistics

Market cap

1.49M

Market cap1.49M

Price-Earnings ratio

-0.09

Price-Earnings ratio-0.09

Dividend yield

—

Dividend yield—

Average volume

48.58K

Average volume48.58K

High today

$0.7299

High today$0.7299

Low today

$0.68

Low today$0.68

Open price

$0.68

Open price$0.68

Volume

17.31K

Volume17.31K

52 Week high

$7.20

52 Week high$7.20

52 Week low

$0.4519

52 Week low$0.4519

Salarius Pharmaceuticals

Why Robinhood?

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. Show more

SLRX Key Statistics

Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor.